<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOTRONEX- alosetron hydrochloride tablet </strong><br>Prometheus Laboratories Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LOTRONEX safely and effectively. See full prescribing information for LOTRONEX.<br>LOTRONEX (alosetron hydrochloride) Tablets<br>Initial U.S. Approval: 2000
</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Infrequent but serious gastrointestinal adverse reactions have been reported with the use of LOTRONEX. These events, including <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> and serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, have resulted in hospitalization and, rarely, blood transfusion, surgery, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> </p>
<ul class="Disc">
<li><span class="Bold">Only prescribers who have enrolled in the Prometheus Prescribing Program for LOTRONEX should prescribe LOTRONEX. (<a href="#s17">5.3</a>)</span></li>
<li><span class="Bold">LOTRONEX is indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) who have not responded adequately to conventional therapy. (<a href="#s3">1</a>)</span></li>
<li><span class="Bold">Discontinue LOTRONEX immediately in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. Do not resume LOTRONEX in patients who develop <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. (<a href="#s5">2.1</a>, <a href="#s15">5.1</a>, <a href="#s16">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Contraindications, Lack of Understanding of Patient Acknowledgement Form (<a href="#s12">4.3</a>)                    09/2010
												 </p>
<p class="Highlighta">Warnings and Precautions, Prescribing Program for LOTRONEX (<a href="#s17">5.3</a>)                                           09/2010
												 </p>
<p class="Highlighta">Patient Counseling Information (<a href="#s59">17</a>)                                                                                                       09/2010
												 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Infrequent but serious gastrointestinal adverse reactions have been reported with the use of LOTRONEX. These events, including <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> and serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, have resulted in hospitalization and, rarely, blood transfusion, surgery, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> </p>
<ul class="Disc">
<li><span class="Bold">Only prescribers who have enrolled in the Prometheus Prescribing Program for LOTRONEX should prescribe LOTRONEX. (<a href="#s17">5.3</a>)</span></li>
<li><span class="Bold">LOTRONEX is indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) who have not responded adequately to conventional therapy. (<a href="#s3">1</a>)</span></li>
<li><span class="Bold">Discontinue LOTRONEX immediately in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. Do not resume LOTRONEX in patients who develop <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. (<a href="#s5">2.1</a>, <a href="#s15">5.1</a>, <a href="#s16">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">LOTRONEX is a selective serotonin 5-HT<span class="Sub">3</span> antagonist indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) who have: 
 </p>
<ul class="Disc">
<li>chronic IBS symptoms (generally lasting 6 months or longer),
</li>
<li>had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and
</li>
<li>not responded adequately to conventional therapy. (<a href="#s3">1</a>)
</li>
</ul>
<p class="Highlighta">Severe IBS includes <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and 1 or more of the following:
 </p>
<ul class="Disc">
<li>frequent and severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>,
</li>
<li>frequent bowel urgency or <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>,
</li>
<li><span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or restriction of daily activities due to IBS. (<a href="#s3">1</a>)
</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Starting dose is 0.5 mg twice a day (<a href="#s5">2.1</a>)
</li>
<li>May increase dose to 1 mg twice a day after 4 weeks if starting dosage is well tolerated but does not adequately control IBS symptoms (<a href="#s5">2.1</a>)
</li>
<li>Discontinue LOTRONEX in patients who have not had adequate control of IBS symptoms after 4 weeks of treatment with 1 mg twice a day. (<a href="#s5">2.1</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 0.5 and 1 mg (<a href="#s8">3</a>)
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Do not initiate in patients with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (<a href="#s10">4.1</a>)
</li>
<li>History of chronic or severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or sequelae from <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, stricture, toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>, and/or <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesions</span>; <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>; impaired intestinal circulation, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, or hypercoagulable state; Crohn's disease or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>; severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#s11">4.2</a>)
</li>
<li>Inability to understand or comply with the Patient Acknowledgement Form (<a href="#s12">4.3</a>)
</li>
<li>Concomitant use of fluvoxamine (<a href="#s13">4.4</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious Complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>: May occur in some patients without warning.  Include obstruction, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, impaction, toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, and secondary <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">bowel ischemia</span> and in rare cases perforation and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported.  Risk is increased in patients who are elderly, debilitated, or taking medications that decrease bowel motility. (<a href="#s15">5.1</a>)
</li>
<li>Discontinue LOTRONEX immediately if <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> occurs. (<a href="#s15">5.1</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span>: May occur in some patients without warning. Promptly evaluate patients with signs of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> (e.g., <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, new or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>). (<a href="#s16">5.2</a>)
</li>
<li>Discontinue LOTRONEX immediately if signs of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> occur, such as <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, or new or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. (<a href="#s16">5.2</a>)
</li>
<li>To prescribe LOTRONEX, prescriber must be enrolled in the Prescribing Program for LOTRONEX and adhere to all components of the Program. (<a href="#s17">5.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence &gt;2% and &gt;placebo) in clinical studies were <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal discomfort</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. (<a href="#s19">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Prometheus at 1-888-423-5227 or FDA at 1-800-FDA-1088 or</span> <span class="Bold Underline">www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron.  Use with fluvoxamine is contraindicated. (<a href="#s12">4.3</a>, <a href="#s27">7.1</a>)
</li>
<li>CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (<a href="#s28">7.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: Contraindicated in severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Use with caution in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#s11">4.2</a>, <a href="#s36">8.6</a>)
</li>
<li>Geriatric use: Elderly patients may be at greater risk for complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. (<a href="#s35">8.5</a>)
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS
</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Patients
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Information for Pharmacists
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 History of Severe Bowel or Hepatic Disorders
</a></h2>
<h2><a href="#section-4.3" class="toc">4.3 Lack of Understanding of Patient Acknowledgement Form
</a></h2>
<h2><a href="#section-4.4" class="toc">4.4 Concomitant Use of Fluvoxamine
</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Serious Complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic Colitis</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Prescribing Program for LOTRONEX
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CYP1A2 Inhibitors
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CYP3A4 Inhibitors
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Other CYP Enzymes
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Dose-Ranging Study
</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Efficacy Studies
</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Long-Term Use
</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES
</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS
</h1>
<p class="First"><span class="Bold">Infrequent but serious gastrointestinal adverse reactions have been reported with the use of LOTRONEX. These events, including <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> and serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, have resulted in hospitalization, and rarely, blood transfusion, surgery, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<ul class="Disc">
<li>
<span class="Bold">The Prescribing Program for LOTRONEX was implemented to help reduce risks of serious gastrointestinal adverse reactions. Only prescribers who have enrolled in the Prometheus Prescribing Program for LOTRONEX, based on their understanding of the benefits and risks, should prescribe LOTRONEX </span><span class="Bold Italics">[see Warnings and Precautions (<a href="#s17">5.3</a>)].</span>
</li>
<li>
<span class="Bold">LOTRONEX is indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) who have not responded adequately to conventional therapy
</span><span class="Bold Italics">[see Indications and Usage (<a href="#s3">1</a>)]</span><span class="Bold">. Before receiving the initial prescription for LOTRONEX, the patient must read and sign the Patient Acknowledgement Form for LOTRONEX
</span><span class="Bold Italics">[see Patient Counseling Information (<a href="#s59">17</a>)].</span>
</li>
<li><span class="Bold">LOTRONEX should be discontinued immediately in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. Patients should immediately report <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> to their prescriber. LOTRONEX should not be resumed in patients who develop <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. Patients who have <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> should immediately contact their prescriber if the <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> does not resolve after LOTRONEX is discontinued. Patients with resolved <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> should resume LOTRONEX only on the advice of their treating prescriber <span class="Italics">[see Dosage and Administration (<a href="#s5">2.1</a>), Warnings and Precautions (<a href="#s15">5.1</a>), (<a href="#s16">5.2</a>)].</span></span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First"> LOTRONEX is indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) who have:
</p>
<ul class="Disc">
<li>chronic IBS symptoms (generally lasting 6 months or longer),
</li>
<li>had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and
</li>
<li>not responded adequately to conventional therapy.
</li>
</ul>
<p> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>-predominant IBS is severe if it includes <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and one or more of the following:
</p>
<ul class="Disc">
<li>frequent and severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>,
</li>
<li>frequent bowel urgency or <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>,
</li>
<li><span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or restriction of daily activities due to IBS.
</li>
</ul>
<p> Because of infrequent but serious gastrointestinal adverse reactions associated with LOTRONEX, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable.
</p>
<p> Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX in men.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First"> For safety reasons, only prescribers who enroll in the Prometheus Prescribing Program for LOTRONEX should prescribe LOTRONEX <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.3</a>)].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Patients
</h2>
<p class="First">
									To lower the risk of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, LOTRONEX should be started at a dosage of 0.5 mg twice a day. Patients who become constipated at this dosage should stop taking LOTRONEX until the <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> resolves. They may be restarted at 0.5 mg once a day. If <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> recurs at the lower dose, LOTRONEX should be discontinued immediately.
								</p>
<p>
									Patients well controlled on 0.5 mg once or twice a day may be maintained on this regimen. If after 4 weeks the dosage is well tolerated but does not adequately control IBS symptoms, then the dosage can be increased to up to 1 mg twice a day<span class="Bold">.  LOTRONEX should be discontinued in patients who have not had adequate control of IBS symptoms after 4 weeks of treatment with 1 mg twice a day.</span></p>
<p> LOTRONEX can be taken with or without food <span class="Italics">[see Clinical Pharmacology (<a href="#s43">12.3</a>)]</span>.
</p>
<p> LOTRONEX should be discontinued immediately in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or signs of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. LOTRONEX should not be restarted in patients who develop <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>.
</p>
<p> Clinical trial and postmarketing experience suggest that debilitated patients or patients taking additional medications that decrease gastrointestinal motility may be at greater risk of serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Therefore, appropriate caution and follow-up should be exercised if LOTRONEX is prescribed for these patients.
</p>
<p> Postmarketing experience suggests that elderly patients may be at greater risk for complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; therefore, appropriate caution and follow-up should be exercised if LOTRONEX is prescribed for these patients <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First"> LOTRONEX is extensively metabolized by the liver, and increased exposure to LOTRONEX is likely to occur in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Increased drug exposure may increase the risk of serious adverse reactions. LOTRONEX should be used with caution in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Contraindications (<a href="#s9">4</a>), Use in Specific Populations (<a href="#s36">8.6</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Information for Pharmacists
</h2>
<p class="First"> LOTRONEX may be dispensed only on presentation of a prescription for LOTRONEX with a sticker for the Prescribing Program for LOTRONEX attached. A Medication Guide for LOTRONEX must be given to the patient each time LOTRONEX is dispensed as required by law. No telephone, facsimile, or computerized prescriptions are permitted with this program. Refills are permitted to be written on prescriptions.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s8"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First"> 0.5 mg and 1 mg tablets
</p>
<p> LOTRONEX Tablets, 0.5 mg (0.562 mg alosetron HCl equivalent to 0.5 mg alosetron), are white, oval, film-coated tablets debossed with GX EX1 on one face.
</p>
<p> LOTRONEX Tablets, 1 mg (1.124 mg alosetron HCl equivalent to 1 mg alosetron), are blue, oval, film-coated tablets debossed with GX CT1 on one face.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s9"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</h2>
<p class="First"> LOTRONEX <span class="Bold">should not be initiated</span> in patients with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-4.2"></a><p></p>
<h2>4.2 History of Severe Bowel or Hepatic Disorders
</h2>
<p class="First"> LOTRONEX is contraindicated in patients with a history of the following:
</p>
<ul class="Disc">
<li>chronic or severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or sequelae from <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, stricture, toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span>, and/or <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesions</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>, impaired intestinal circulation, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, or hypercoagulable state
</li>
<li>Crohn's disease or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>
</li>
<li>severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-4.3"></a><p></p>
<h2>4.3 Lack of Understanding of Patient Acknowledgement Form
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>LOTRONEX should not be used by patients who are unable to understand or comply with the Patient Acknowledgement Form for LOTRONEX <span class="Italics">[see Patient Counseling Information (<a href="#s59">17</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-4.4"></a><p></p>
<h2>4.4 Concomitant Use of Fluvoxamine
</h2>
<p class="First"> Concomitant administration of LOTRONEX with fluvoxamine is contraindicated. Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold <span class="Italics">[see Drug Interactions (<a href="#s27">7.1</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s14"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Serious Complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</h2>
<p class="First"><span class="Bold">Some patients have experienced serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> without warning.</span></p>
<p> Serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, including obstruction, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, impaction, toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, and secondary <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">bowel ischemia</span>, have been reported with use of LOTRONEX during clinical trials. Complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> have been reported with use of 1 mg twice daily and with lower doses. A dose response relationship has not been established for serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. <span class="Bold">The incidence of serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was approximately 0.1% (1 per 1,000 patients) in women receiving either LOTRONEX or placebo.</span> In addition, rare cases of perforation and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported from postmarketing clinical practice. In some cases, complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> required intestinal surgery, including colectomy. Patients who are elderly, debilitated, or taking additional medications that decrease gastrointestinal motility may be at greater risk for complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.
</p>
<p> LOTRONEX should be discontinued immediately in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> <span class="Italics">[see <a href="#s1">Boxed Warning</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic Colitis</span>
</h2>
<p class="First"><span class="Bold">Some patients have experienced <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> without warning.</span></p>
<p> <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> has been reported in patients receiving LOTRONEX in clinical trials as well as during marketed use of the drug. <span class="Bold">In IBS clinical trials, the cumulative incidence of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> in women receiving LOTRONEX was 0.2% (2 per 1,000 patients, 95% confidence interval 1 to 3) through 3 months and was 0.3% (3 per 1,000 patients, 95% confidence interval 1 to 4) through 6 months.</span> <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> has been reported with use of 1 mg twice daily and with lower doses. A dose-response relationship has not been established. <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> was reported in one patient receiving placebo.  The patient experience in controlled clinical trials is insufficient to estimate the incidence of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> in patients taking LOTRONEX for longer than 6 months.
</p>
<p> LOTRONEX should be discontinued immediately in patients with signs of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> such as <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, or new or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. Because <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> can be life-threatening, patients with signs or symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> should be evaluated promptly and have appropriate diagnostic testing performed. Treatment with LOTRONEX should not be resumed in patients who develop <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Prescribing Program for LOTRONEX
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>To prescribe LOTRONEX, the prescriber must be enrolled in the Prescribing Program for LOTRONEX. To enroll, prescribers must understand the benefits and risks of treatment with LOTRONEX for severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS, including the information in the Prescribing Information, Medication Guide, and Patient Acknowledgement Form for LOTRONEX.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>To enroll in the Prescribing Program for LOTRONEX, call 1-888-423-5227 or visit www.lotronexppl.com to complete the Prescriber Enrollment Form.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s18"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First"> The following adverse reactions are described in more detail in other sections of the label:
</p>
<ul class="Disc">
<li>Complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Warnings and Precautions (<a href="#s15">5.1</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> <span class="Italics">[see <a href="#s1">Boxed Warning</a>, Warnings and Precautions (<a href="#s16">5.2</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First"> Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="e19"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Patients With <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span>:
</span><a href="#t1">Table 1</a> summarizes adverse reactions from 22 repeat-dose studies in patients with IBS who were treated with 1 mg of LOTRONEX twice daily for 8 to 24 weeks. The adverse reactions in Table 1 were reported in 1% or more of patients who received LOTRONEX and occurred more frequently on LOTRONEX than on placebo. A statistically significant difference was observed for <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> in patients treated with LOTRONEX compared to placebo (p&lt;0.0001).
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1. Adverse Reactions Reported in ≥1% of Patients With <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> and More Frequently on LOTRONEX 1 mg Twice Daily Than Placebo
</span></caption>
<col align="left" width="45.085%">
<col align="left" width="27.458%">
<col align="left" width="27.458%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Rrule Toprule" align="center" valign="middle"></td>
<td class="Rrule Toprule" align="center" valign="middle">LOTRONEX
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">Body System
</td>
<td class="Rrule" align="center" valign="middle">Placebo
</td>
<td class="Rrule" align="center" valign="middle">1 mg twice daily
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">Adverse Reaction
</td>
<td class="Botrule Rrule" align="center" valign="middle">(n = 2,363)
</td>
<td class="Botrule Rrule" align="center" valign="middle">(n = 8,328)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Gastrointestinal
</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Rrule" align="center" valign="middle">6%
</td>
<td class="Rrule" align="center" valign="middle">29%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
</td>
<td class="Rrule" align="center" valign="middle">4%
</td>
<td class="Rrule" align="center" valign="middle">7%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Rrule" align="center" valign="middle">5%
</td>
<td class="Rrule" align="center" valign="middle">6%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Gastrointestinal discomfort</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
</td>
<td class="Rrule" align="center" valign="middle">3%
</td>
<td class="Rrule" align="center" valign="middle">5%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>
</td>
<td class="Rrule" align="center" valign="middle">1%
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">Regurgitation</span> and reflux
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1%
</td>
<td class="Botrule Rrule" align="center" valign="middle">2%
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is a frequent and dose-related side effect of treatment with LOTRONEX <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.1</a>)]</span>. In clinical studies <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was reported in approximately 29% of patients with IBS treated with LOTRONEX 1 mg twice daily (n = 9,316). This effect was statistically significant compared to placebo (p&lt;0.0001). Eleven percent (11%) of patients treated with LOTRONEX 1 mg twice daily withdrew from the studies due to <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Although the number of patients with IBS treated with LOTRONEX 0.5 mg twice daily is relatively small (n = 243), only 11% of those patients reported <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and 4% withdrew from clinical studies due to <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Among the patients treated with LOTRONEX 1 mg twice daily who reported <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, 75% reported a single episode and most reports of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (70%) occurred during the first month of treatment, with the median time to first report of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> onset of 8 days. Occurrences of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> in clinical trials were generally mild to moderate in intensity, transient in nature, and resolved either spontaneously with continued treatment or with an interruption of treatment. However, serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> have been reported in clinical studies and in postmarketing experience <span class="Italics">[see <a href="#s1">Boxed Warning</a> and Warnings and Precautions (<a href="#s15">5.1</a>)]</span>. In Studies 1 and 2, 9% of patients treated with LOTRONEX reported <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and 4 consecutive days with no bowel movement <span class="Italics">[see Clinical Studies (<a href="#s51">14.2</a>)]</span>. Following interruption of treatment, 78% of the affected patients resumed bowel movements within a 2-day period and were able to re-initiate treatment with LOTRONEX.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Italics">Hepatic</span>: A similar incidence in elevation of ALT (&gt;2-fold) was seen in patients receiving LOTRONEX or placebo (1.0% vs. 1.2%). A single case of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (elevated ALT, AST, alkaline phosphatase, and bilirubin) without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> in a patient receiving LOTRONEX was reported in a 12-week study. A causal association with LOTRONEX has not been established.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e22"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Italics">Long-Term Safety</span>: Patient experience in controlled clinical trials is insufficient to estimate the incidence of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> in patients taking LOTRONEX for longer than 6 months.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Underline">Women With Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>-Predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span>:
</span><a href="#t2">Table 2</a> summarizes the gastrointestinal adverse reactions from 1 repeat-dose study in female patients with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS who were treated for 12 weeks. The adverse reactions in Table 2 were reported in 3% or more of patients who received LOTRONEX and occurred more frequently with LOTRONEX than with placebo. Other events reported in 3% or more of patients who received LOTRONEX and occurring more frequently with LOTRONEX than with placebo included <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="201218" conceptname="Epidemic vomiting syndrome">viral gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2. Gastrointestinal Adverse Reactions Reported in ≥3% of Women With Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>-Predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> and More Frequently on LOTRONEX Than Placebo.
</span></caption>
<col align="left" width="20.520%">
<col align="left" width="15.080%">
<col align="left" width="22.720%">
<col align="left" width="20.840%">
<col align="left" width="20.840%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Rrule Toprule" align="center" valign="middle"></td>
<td class="Rrule Toprule" align="center" valign="middle">LOTRONEX
</td>
<td class="Rrule Toprule" align="center" valign="middle">LOTRONEX
</td>
<td class="Rrule Toprule" align="center" valign="middle">LOTRONEX
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Adverse Reaction
</td>
<td class="Rrule" align="center" valign="middle">Placebo
</td>
<td class="Rrule" align="center" valign="middle">0.5 mg once daily
</td>
<td class="Rrule" align="center" valign="middle">1 mg once daily
</td>
<td class="Rrule" align="center" valign="middle">1 mg twice daily
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="middle">(n = 176)
</td>
<td class="Botrule Rrule" align="center" valign="middle">(n = 175)
</td>
<td class="Botrule Rrule" align="center" valign="middle">(n = 172)
</td>
<td class="Botrule Rrule" align="center" valign="middle">(n = 176)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Rrule" align="center" valign="middle">5%
</td>
<td class="Rrule" align="center" valign="middle">9%
</td>
<td class="Rrule" align="center" valign="middle">16%
</td>
<td class="Rrule" align="center" valign="middle">19%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>
</td>
<td class="Rrule" align="center" valign="middle">3%
</td>
<td class="Rrule" align="center" valign="middle">5%
</td>
<td class="Rrule" align="center" valign="middle">6%
</td>
<td class="Rrule" align="center" valign="middle">7%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
<td class="Rrule" align="center" valign="middle">3%
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">Hemorrhoidal<br>     <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
<td class="Rrule" align="center" valign="middle">3%
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span>
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
<td class="Rrule" align="center" valign="middle">1%
</td>
<td class="Rrule" align="center" valign="middle">3%
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span>
</td>
<td class="Rrule" align="center" valign="middle">2%
</td>
<td class="Rrule" align="center" valign="middle">1%
</td>
<td class="Rrule" align="center" valign="middle">1%
</td>
<td class="Rrule" align="center" valign="middle">3%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><br>     upper
</td>
<td class="Botrule Rrule" align="center" valign="middle">1%
</td>
<td class="Botrule Rrule" align="center" valign="middle">3%
</td>
<td class="Botrule Rrule" align="center" valign="middle">1%
</td>
<td class="Botrule Rrule" align="center" valign="middle">1%
</td>
</tr>
</tbody>
</table>
<p> Adverse reactions reported in another study of 701 women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS were similar to those shown in <a href="#t2">Table 2</a>. Gastrointestinal adverse reactions reported in 3% or more of patients who received LOTRONEX and occurring more frequently with LOTRONEX than with placebo included <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (14% and 10% of patients taking LOTRONEX 1 mg twice daily or 0.5 mg as needed, respectively, compared with 2% taking placebo), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>. Other events reported in 3% or more of patients who received LOTRONEX and occurring more frequently with LOTRONEX than with placebo included <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="201218" conceptname="Epidemic vomiting syndrome">viral gastroenteritis</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>:</span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> was the most frequent adverse reaction among women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS represented in <a href="#t2">Table 2</a>. There was a dose response in the groups treated with LOTRONEX in the number of patients withdrawn due to <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (2% on placebo, 5% on 0.5 mg once daily, 8% on 1 mg once daily, and 11% on 1 mg twice daily). Among these patients with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS treated with LOTRONEX who reported <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> most (75%) reported one episode which occurred within the first 15 days of treatment and persisted for 4 to 5 days.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-6.1.7"></a><p></p>
<p class="First"><span class="Underline">Other Events Observed During Clinical Evaluation of LOTRONEX:</span> During its assessment in clinical trials, multiple and single doses of LOTRONEX were administered, resulting in 11,874 subject exposures in 86 completed clinical studies. The conditions, dosages, and duration of exposure to LOTRONEX varied between trials, and the studies included healthy male and female volunteers as well as male and female patients with IBS and other indications.
</p>
<p> In the listing that follows, reported adverse reactions were classified using a standardized coding dictionary. Only those events that an investigator believed were possibly related to LOTRONEX, occurred in at least 2 patients, and occurred at a greater frequency during treatment with LOTRONEX than during placebo administration are presented. Serious adverse reactions occurring in at least 1 patient for whom an investigator believed there was reasonable possibility that the event was related to treatment with LOTRONEX and occurring at a greater frequency in patients treated with LOTRONEX than placebo-treated patients are also presented.
</p>
<p> In the following listing, events are categorized by body system. Within each body system, events are presented in descending order of frequency. The following definitions are used: <span class="Italics">infrequent</span> adverse reactions are those occurring on one or more occasion in 1/100 to 1/1,000 patients; <span class="Italics">rare</span> adverse reactions are those occurring on one or more occasion in fewer than 1/1,000 patients.
</p>
<p> Although the events reported occurred during treatment with LOTRONEX, they were not necessarily caused by it.
</p>
<dl>
<dt> 
</dt>
<dd>
<span class="Italics">Blood and Lymphatic: Rare:</span> Quantitative red cell or hemoglobin defects, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Cardiovascular: Infrequent:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachyarrhythmias</span>.  <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, and <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Drug Interaction, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span>, and <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span>: Rare:</span> <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusions</span> and <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Ear, Nose, and Throat: Rare:</span> Ear, nose, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span>; viral ear, nose, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span>; and <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Endocrine and Metabolic: Rare:</span> Disorders of calcium and phosphate metabolism, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, hypothalamus/pituitary hypofunction, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and fluid disturbances.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Eye: Rare:</span> Light sensitivity of eyes.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Gastrointestinal: Infrequent:</span> Hyposalivation, dyspeptic symptoms, gastrointestinal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>)]</span>, and gastrointestinal lesions.  <span class="Italics">Rare:</span> Abnormal <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, gastrointestinal signs and symptoms, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, positive fecal occult blood, <span class="product-label-link" type="condition" conceptid="4265627" conceptname="Hyperchlorhydria">hyperacidity</span>, decreased gastrointestinal motility and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstructions</span>, oral symptoms, gastrointestinal <span class="product-label-link" type="condition" conceptid="4149485" conceptname="Intussusception">intussusception</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="195306" conceptname="Gastroduodenitis">gastroduodenitis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, and <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Hepatobiliary Tract and Pancreas: Rare:</span> Abnormal bilirubin levels and <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Lower Respiratory: Infrequent:</span> Breathing disorders.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Musculoskeletal: Rare:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle pain</span>; <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle stiffness</span>, tightness and <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>; and bone and <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Neurological: Infrequent:</span> Hypnagogic effects.  <span class="Italics">Rare:</span> Memory effects, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, dreams, cognitive function disorders, disturbances of sense of taste, disorders of equilibrium, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, sedation, and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Non-Site Specific: Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, temperature regulation disturbances.  <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">Burning sensations</span>, hot and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensations, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensations, and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Psychiatry: Infrequent:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>.  <span class="Italics">Rare:</span> Depressive moods.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Reproduction: Rare:</span> Sexual function disorders, female reproductive tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, reproductive <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and fungal reproductive <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Skin: Infrequent:</span> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span> and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>; <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> and <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>; disorders of sweat and sebum; <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reaction</span>; <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>; <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span>; <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> and <span class="product-label-link" type="condition" conceptid="4317258" conceptname="Disorder of skin">dermatosis</span>; and <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorders</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Urology: Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4128384" conceptname="Non-infective cystitis">Bladder inflammation</span>; <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>; and urinary tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First"> In addition to events reported in clinical trials, the following events have been identified during use of LOTRONEX in clinical practice. Because they were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to LOTRONEX.
</p>
<dl>
<dt> 
</dt>
<dd>
<span class="Underline">Gastrointestinal:</span> Impaction, perforation, ulceration, small bowel <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">mesenteric ischemia</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Underline">Neurological:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Underline">Skin:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>.
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s26"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<p class="First"><span class="Italics">In vivo</span> data suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CYP1A2 Inhibitors
</h2>
<p class="First"> Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9, and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg/ day for 16 days, with coadministration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and fluvoxamine is contraindicated <span class="Italics">[see Contraindications (<a href="#s12">4.3</a>)]</span>.
</p>
<p> Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CYP3A4 Inhibitors
</h2>
<p class="First"> Ketoconazole is a known strong inhibitor of CYP3A4. In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day. Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%. Caution should be used when alosetron and ketoconazole are administered concomitantly. Coadministration of alosetron and strong CYP3A4 inhibitors such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions. The effect of induction or inhibition of other pathways on exposure to alosetron and its metabolites is not known.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Other CYP Enzymes
</h2>
<p class="First"><span class="Italics">In vitro</span> human liver microsome studies and an <span class="Italics">in vivo</span> metabolic probe study demonstrated that alosetron did not inhibit CYP enzymes 3A4, 2C9, or 2C19. <span class="Italics">In vitro</span> at total drug concentrations 27-fold higher than peak plasma concentrations observed with the 1 mg dose, alosetron inhibited CYP enzymes 1A2 (60%) and 2E1 (50%). In an <span class="Italics">in vivo</span> metabolic probe study, alosetron did not inhibit CYP2E1 but did produce 30% inhibition of both CYP1A2 and N-acetyltransferase. Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride. No significant effects on cisapride metabolism or QT interval were noted. The effects of alosetron on monoamine oxidases and on intestinal first pass secondary to high intraluminal concentrations have not been examined. Based on the above data from <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> studies, it is unlikely that alosetron will inhibit the hepatic metabolic clearance of drugs metabolized by the CYP enzymes 2C9, 2C19, or 2E1.
</p>
<p> Alosetron does not appear to induce the major cytochrome P450 drug-metabolizing enzyme 3A. Alosetron also does not appear to induce CYP enzymes 2E1 or 2C19. It is not known whether alosetron might induce other enzymes.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s30"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s31"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s32"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Teratogenic Effects:</span> Pregnancy Category B. Reproduction studies have been performed in rats at doses up to 40 mg/kg/day (about 160 times the recommended human dose based on body surface area) and rabbits at oral doses up to 30 mg/kg/day (about 240 times the recommended daily human dose based on body surface area). These studies have revealed no evidence of impaired fertility or harm to the fetus due to alosetron. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, LOTRONEX should be used during pregnancy only if clearly needed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s33"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First"> Alosetron and/or metabolites of alosetron are excreted in the breast milk of lactating rats. It is not known whether alosetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when LOTRONEX is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s34"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First"> Safety and effectiveness in pediatric patients have not been established.  Use of LOTRONEX is not recommended in the pediatric population, based upon the risk of serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> in adults.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s35"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First"> In some studies in healthy men or women, plasma concentrations were elevated by approximately 40% in individuals 65 years and older compared to young adults <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.1</a>)]</span>. However, this effect was not consistently observed in men.
</p>
<p> Postmarketing experience suggests that elderly patients may be at greater risk for complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> therefore, appropriate caution and follow-up should be exercised if LOTRONEX is prescribed for these patients <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First"> Due to the extensive hepatic metabolism of alosetron, increased exposure to alosetron and/or its metabolites is likely to occur in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Alosetron should not be used in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and should be used with caution in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</p>
<p> A single 1 mg oral dose of alosetron was administered to 1 female and 5 male patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of 7 to 9) and to 1 female and 2 male patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score of &gt;9). In comparison with historical data from healthy subjects, patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> displayed higher systemic exposure to alosetron. The female with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> displayed approximately 14-fold higher exposure, while the female with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> displayed approximately 1.6-fold higher exposure, than healthy females. Due to the small number of subjects and high intersubject variability in the pharmacokinetic findings, no definitive quantitative conclusions can be made. However, due to the greater exposure to alosetron in the female with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, alosetron should not be used in females with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Dosage and Administration (<a href="#s6">2.2</a>), Contraindications (<a href="#s9">4</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> (creatinine clearance 4 to 56 mL/min) has no effect on the renal elimination of alosetron due to the minor contribution of this pathway to elimination. The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on metabolite pharmacokinetics and the effect of end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> have not been assessed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s38"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First"> There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of LOTRONEX. Patients should be managed with appropriate supportive therapy. Individual oral doses as large as 16 mg have been administered in clinical studies without significant adverse reactions. This dose is 8 times higher than the recommended total daily dose. Inhibition of the metabolic elimination and reduced first pass of other drugs might occur with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of LOTRONEX <span class="Italics">[see Drug Interactions (<a href="#s26">7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s39"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First"> The active ingredient in LOTRONEX Tablets is alosetron hydrochloride (HCl), a potent and selective antagonist of the serotonin 5-HT<span class="Sub">3</span> receptor type. Chemically, alosetron is designated as 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride. Alosetron is achiral and has the empirical formula C<span class="Sub">17</span>H<span class="Sub">18</span>N<span class="Sub">4</span>O•HCl, representing a molecular weight of 330.8. Alosetron is a white to beige solid that has a solubility of 61 mg/mL in water, 42 mg/mL in 0.1M hydrochloric acid, 0.3 mg/mL in pH 6 phosphate buffer, and &lt;0.1 mg/mL in pH 8 phosphate buffer. The chemical structure of alosetron is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526ba44c-a476-4675-a63c-4d0a72b723f5&amp;name=lot00-0006-01.jpg">
</div>
<p> LOTRONEX Tablets are supplied for oral administration as 0.5 mg (white) and 1 mg (blue) tablets. The 0.5 mg tablet contains 0.562 mg alosetron HCl equivalent to 0.5 mg alosetron, and the 1 mg tablet contains 1.124 mg alosetron HCl equivalent to 1 mg of alosetron. Each tablet also contains the inactive ingredients lactose (anhydrous), magnesium stearate, microcrystalline cellulose, and pregelatinized starch. The white film coat for the 0.5 mg tablet contains hypromellose, titanium dioxide, and triacetin. The blue film coat for the 1 mg tablet contains hypromellose, titanium dioxide, triacetin, and indigo carmine.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s40"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s41"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First"> Alosetron is a potent and selective 5-HT<span class="Sub">3</span> receptor antagonist. 5-HT<span class="Sub">3</span> receptors are ligand-gated cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of <span class="product-label-link" type="condition" conceptid="4251315" conceptname="Visceral pain">visceral pain</span>, colonic transit, and gastrointestinal secretions, processes that relate to the pathophysiology of IBS. 5-HT<span class="Sub">3</span> receptor antagonists such as alosetron inhibit activation of non-selective cation channels, which results in the modulation of the enteric nervous system.
</p>
<p> The cause of IBS is unknown. IBS is characterized by visceral <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> of the gastrointestinal tract, which lead to abnormal sensations of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and motor activity. Following <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> of the rectum, patients with IBS exhibit <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> at lower volumes than healthy volunteers. Following such <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, alosetron reduced <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and exaggerated motor responses, possibly due to blockade of 5-HT<span class="Sub">3</span> receptors.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s42"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First"> In healthy volunteers and patients with IBS, alosetron (2 mg orally, twice daily for 8 days) increased colonic transit time without affecting orocecal transit time. In healthy volunteers, alosetron also increased basal jejunal water and sodium absorption after a single 4 mg dose. In patients with IBS, multiple oral dosages of alosetron (4 mg twice daily for 6.5 days) significantly increased colonic compliance.
</p>
<p> Single oral doses of alosetron administered to healthy men produced a dose-dependent reduction in the flare response seen after intradermal injection of serotonin. Urinary 6-β-hydroxycortisol excretion decreased by 52% in elderly subjects after 27.5 days of alosetron 2 mg administered orally twice daily. This decrease was not statistically significant. In another study utilizing alosetron 1 mg administered orally twice daily for 4 days, there was a significant decrease in urinary 6-β-hydroxycortisol excretion. However, there was no change in the ratio of 6-β-hydroxycortisol to cortisol, indicating a possible decrease in cortisol production. The clinical significance of these findings is unknown.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s43"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First"> The pharmacokinetics of alosetron have been studied after single oral doses ranging from 0.05 to 16 mg in healthy men. The pharmacokinetics of alosetron have also been evaluated in healthy women and men and in patients with IBS after repeated oral dosages ranging from 1 mg twice daily to 8 mg twice daily.
</p>
<p><span class="Underline">Absorption:</span> Alosetron was rapidly absorbed after oral administration with a mean absolute bioavailability of approximately 50% to 60% (approximate range, 30% to &gt;90%). After administration of radiolabeled alosetron, only 1% of the dose was recovered in the feces as unchanged drug. Following oral administration of a 1 mg alosetron dose to young men, a peak plasma concentration of approximately 5 ng/mL occurred at 1 hour. In young women, the mean peak plasma concentration was approximately 9 ng/mL, with a similar time to peak.
</p>
<p> Plasma concentrations were 30% to 50% lower and less variable in men compared to women given the same oral dose. Population pharmacokinetic analysis in IBS patients confirmed that alosetron concentrations were influenced by gender (27% lower in men).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Food Effects:</span> Alosetron absorption is decreased by approximately 25% by co-administration with food, with a mean delay in time to peak concentration of 15 minutes <span class="Italics">[see Dosage and Administration (<a href="#s5">2.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution:</span> Alosetron demonstrates a volume of distribution of approximately 65 to 95 L. Plasma protein binding is 82% over a concentration range of 20 to 4,000 ng/mL.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism and Elimination:</span> Plasma concentrations of alosetron increase proportionately with increasing single oral doses up to 8 mg and more than proportionately at a single oral dose of 16 mg. Twice-daily oral dosing of alosetron does not result in accumulation. The terminal elimination half-life of alosetron is approximately 1.5 hours (plasma clearance is approximately 600 mL/min). Population pharmacokinetic analysis in patients with IBS confirmed that alosetron clearance is minimally influenced by doses up to 8 mg.
</p>
<p> Renal elimination of unchanged alosetron accounts for only 13% of the dose. Renal clearance is approximately 112 mL/min.
</p>
<p> A study with <span class="Sup">14</span>C-labeled alosetron in Caucasian males (n = 3) and females (n = 3) and an Asian male (n = 1) showed similar serum metabolite profiles. Unchanged alosetron was the major component in serum, with other metabolites being present at low concentrations, none amounting to more than 15% of the unmetabolized alosetron concentration. The circulating metabolites were identified as 6-hydroxy glucuronide, 6-hydroxy sulphate, 7-hydroxy sulphate, hydroxymethyl imidazole, and mono- and bis-oxygenated imidazole derivatives of alosetron. The metabolites are unlikely to contribute to the biological activity of alosetron. Of the circulating Phase I metabolites, only the hydroxymethyl imidazole has weak pharmacological activity, around 10-fold less potent than alosetron. Total recovery of radioactivity in the excreta was 85 ± 6%. The majority of the radiolabeled dose is excreted in the urine (74 ± 5%). The major urinary metabolites were the 6-hydroxy glucuronide and the mono- and bis-oxygenated imidazole derivatives of alosetron. 11 ± 4% of the radiolabeled dose was excreted in the feces with less than 1% of the dose being excreted as the unchanged alosetron.
</p>
<p> Alosetron is metabolized by human microsomal cytochrome P450 (CYP), shown <span class="Italics">in vitro</span> to involve enzymes 2C9 (30%), 3A4 (18%), and 1A2 (10%). Non–CYP-mediated Phase I metabolic conversion also contributes to an extent of about 11%. However, <span class="Italics">in vivo</span> data suggest that CYP1A2 plays a more prominent role in alosetron metabolism (62 to 97% of alosetron clearance) based on correlation of alosetron clearance with <span class="Italics">in vivo</span> CYP1A2 activity measured by probe substrate, increased clearance induced by smoking, and inhibition of clearance by fluvoxamine <span class="Italics">[see Contraindications (<a href="#s9">4</a>), Drug Interactions (<a href="#s26">7</a>)].</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s47"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s48"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First"> In 2-year oral studies, alosetron was not carcinogenic in mice at doses up to 30 mg/kg/day or in rats at doses up to 40 mg/kg/day. These doses are about 60 to 160 times, respectively, the recommended human dose of alosetron of 2 mg/day (1 mg twice daily) based on body surface area. Alosetron was not genotoxic in the Ames tests, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (L5178Y/TK<span class="Sup">±</span>) forward gene mutation test, the human lymphocyte chromosome aberration test, the ex vivo rat hepatocyte unscheduled DNA synthesis (UDS) test, or the <span class="Italics">in vivo</span> rat micronucleus test for mutagenicity. Alosetron at oral doses up to 40 mg/kg/day (about 160 times the recommended daily human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male or female rats.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s49"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Dose-Ranging Study
</h2>
<p class="First"> Data from a dose-ranging study of women (n = 85) who received LOTRONEX 0.5 mg twice daily indicated that the incidence of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (14%) was lower than that experienced by women receiving 1 mg twice daily (29%). Therefore, to lower the risk of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, LOTRONEX should be started at a dosage of 0.5 mg twice a day. The efficacy of the 0.5 mg twice-daily dosage in treating severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS has not been adequately evaluated in clinical trials. <span class="Italics">[See Dosage and Administration (<a href="#s5">2.1</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Efficacy Studies
</h2>
<p class="First"> LOTRONEX has been studied in women with IBS in five 12-week US multicenter, randomized, double-blind, placebo-controlled clinical studies.
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3. Efficacy Studies Conducted in Women With <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span> (IBS)
</span></caption>
<col align="left" width="11.353%">
<col align="left" width="47.287%">
<col align="left" width="13.078%">
<col align="left" width="28.282%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Study
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Patient Population
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Placebo<br>(n)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">LOTRONEX<br>Dose<br>(n)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">1 and 2
</td>
<td class="Botrule Rrule" align="center" valign="middle">Non-constipated women with IBS
</td>
<td class="Botrule Rrule" align="center" valign="middle">(640)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 mg twice daily<br>(633)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">3 and 4
</td>
<td class="Botrule Rrule" align="center" valign="middle">Women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS (defined as bowel urgency ≥50% of days)
</td>
<td class="Botrule Rrule" align="center" valign="middle">(515)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 mg twice daily<br>(778)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="middle">5
</td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle">Women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS (defined as average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> ≥moderate, urgency ≥50% of days, and/or restriction of daily activities ≥25% of days)
</td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle">(176)
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.5 mg once daily<br>(177)
</td>
</tr>
<tr><td class="Botrule Rrule" align="center" valign="middle">1 mg once daily<br>(175)
</td></tr>
<tr class="Last"><td class="Botrule Rrule" align="center" valign="middle">1 mg twice daily<br>(177)
</td></tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Underline">Studies in Non-Constipated Women with <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span>:</span> Studies 1 and 2 were conducted in non-constipated women with IBS meeting the Rome Criteria<span class="Sup">1</span> for at least 6 months. Women with severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or a history of severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> were excluded. A 2-week run-in period established baseline IBS symptoms.
</p>
<p> About two thirds of the women had <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS. Compared with placebo, 10% to 19% more women with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS who received LOTRONEX had adequate relief of IBS <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> during each month of the study.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-13.2.2"></a><p></p>
<p class="First"> Studies in Women With Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>-Predominant <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">Irritable Bowel Syndrome</span>: LOTRONEX is indicated only for women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS <span class="Italics">[see Indications and Usage (<a href="#s3">1</a>)]</span>. The efficacy of LOTRONEX in this subset of the women studied in clinical trials is supported by prospective and retrospective analyses.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-13.2.3"></a><p></p>
<p class="First"><span class="Italics">Prospective Analyses:</span> Studies 3 and 4 were conducted in women with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS and bowel urgency on at least 50% of days at entry. Women receiving LOTRONEX had significant increases over placebo (13% to 16%) in the median percentage of days with urgency control.
</p>
<p> The lower gastrointestinal functions of stool consistency, stool frequency, and sense of incomplete evacuation were also evaluated by patients' daily reports. Stool consistency was evaluated on a scale of 1 to 5 (1 = very hard, 2 = hard, 3 = formed, 4 = loose, and 5 = watery). At baseline, average stool consistency was approximately 4 (loose) for both treatment groups. During the 12 weeks of treatment, the average stool consistency decreased to approximately 3.0 (formed) for patients who received LOTRONEX and 3.5 for the patients who received placebo in the 2 studies.
</p>
<p> At baseline, average stool frequency was approximately 3.2 per day for both treatment groups. During the 12 weeks of treatment, the average daily stool frequency decreased to approximately 2.1 and 2.2 for patients receiving LOTRONEX and 2.7 and 2.8 for patients receiving placebo in the 2 studies.
</p>
<p> There was no consistent effect upon the sense of incomplete evacuation during the 12 weeks of treatment for patients receiving LOTRONEX as compared to patients receiving placebo in either study.
</p>
<p> Study 5 was conducted in women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS and 1 or more of the following: frequent and severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, frequent bowel urgency or <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or restriction of daily activities due to IBS. To evaluate the proportion of patients who responded to treatment, patients were asked every 4 weeks to compare their IBS symptoms during the previous month of treatment with how they usually felt during the 3 months prior to the study using an ordered 7-point scale (substantially worse to substantially improved). A responder was defined as a subject who reported moderate or substantial improvement on this global improvement scale (GIS). At Week 12, all three groups receiving LOTRONEX had significantly greater percentages of GIS responders compared to the placebo group (43% to 51% vs. 31%) using a Last Observation Carried Forward (LOCF) analysis.  It should be noted that approximately 4% of subjects in each LOTRONEX dose group who were classified as responders using this approach were observed only through week 4.  At each of the 4 week intervals of the treatment phase, all three dosages of LOTRONEX provided improvement in the average adequate relief rate of IBS <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, stool consistency, stool frequency, and sense of urgency compared with placebo.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-13.2.4"></a><p></p>
<p class="First"><span class="Italics">Retrospective Analyses:</span> In analyses of patients from Studies 1 and 2 who had <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS and indicated their baseline run-in IBS symptoms were severe at the start of the trial, LOTRONEX provided greater adequate relief of IBS <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> than placebo. In further analyses of Studies 1 and 2, 57% of patients had urgency at baseline on 5 or more days per week. In this subset, 32% of patients on LOTRONEX had urgency no more than 1 day in the last week of the trial, compared with 19% of patients on placebo.
</p>
<p> In Studies 3 and 4, 66% of patients had urgency at baseline on 5 or more days per week. In this subset, 50% of patients on LOTRONEX had urgency no more than 1 day in the last week of the trial, compared with 29% of patients on placebo. Moreover, in the same subset, 12% on LOTRONEX had urgency no more than 2 days per week in any of the 12 weeks on treatment compared with 1% of placebo patients.
</p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526ba44c-a476-4675-a63c-4d0a72b723f5&amp;name=lot00-0006-02.jpg"><p class="MultiMediaCaption">Figure 1. Percent of Patients With Urgency on &gt;5 Days/Week at Baseline Who Improved to No More Than 1 Day in the Final Week
</p>
</div>
<p> In Studies 1 and 2, patient-reported subjective outcomes related to IBS were assessed by questionnaires obtained at baseline and week 12. Patients in the more severe subset who received LOTRONEX reported less <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">difficulty sleeping</span>, less <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, fewer eating problems, and less interference with social activities and work/main activities due to IBS symptoms or problems compared to those who received placebo. Change in the impact of IBS symptoms and problems on emotional and mental distress and on physical and sexual activity in women who received LOTRONEX were not statistically different from those reported by women who received placebo.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Long-Term Use
</h2>
<p class="First"> In a 48-week multinational, double-blind, placebo-controlled study, LOTRONEX 1 mg twice daily was evaluated in 714 women with non-constipated IBS. A retrospective analysis of the subset of women with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS (urgency on at least 10 days during the 2-week baseline period) was performed. Of the 417 patients with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-predominant IBS, 62% completed the trial.
</p>
<p> LOTRONEX (n = 198) provided a greater average rate of adequate relief of IBS <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (52% vs. 41%) and a greater average rate of satisfactory control of bowel urgency (60% vs. 48%) compared with placebo (n = 219). Significant improvement of these symptoms occurred for most of the 48-week treatment period with no evidence of <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s57"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES
</h1>
<p class="First"> 1. Thompson WG, Creed F, Drossman DA, et al. Functional bowel disease and functional <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. <span class="Italics">Gastroenterol Int</span>. 1992;5:75-91.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s58"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First"> LOTRONEX Tablets, 0.5 mg (0.562 mg alosetron HCl equivalent to 0.5 mg alosetron) are white, oval, film-coated tablets debossed with GX EX1 on one face.
</p>
<p> Bottles of 30 (NDC 65483-894-03) with child-resistant closures.
</p>
<p> LOTRONEX Tablets, 1 mg (1.124 mg alosetron HCl equivalent to 1 mg alosetron), are blue, oval, film-coated tablets debossed with GX CT1 on one face.
</p>
<p> Bottles of 30 (NDC 65483-895-03) with child-resistant closures.
</p>
<p><span class="Bold">Store at 20-25°C (68-77°F) (USP Controlled Room Temperature). Protect from light and moisture.</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s59"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">See Medication Guide</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-16.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Bold">Prescriber and Patient Responsibilities</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Patients should be fully counseled on and understand the risks and benefits of LOTRONEX before an initial prescription is written. The patient may be educated by the enrolled prescriber or a healthcare provider under a prescriber's direction.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline">Prescribers must:</span></p>
<ul class="Disc">
<li style="border-left:1px solid;">
<span class="XmChange"></span>counsel patients for whom LOTRONEX is appropriate about the benefits and risks of LOTRONEX and discuss the impact of IBS symptoms on the patient's life.
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>give the patient a copy of the Medication Guide, which outlines the benefits and risks of LOTRONEX, and instruct the patient to read it carefully. Answer all questions the patient may have about LOTRONEX. The complete text of the Medication Guide is printed at the end of this document.
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>review the Patient Acknowledgement Form for LOTRONEX with the patient, answer all questions, and give a copy of the signed Patient Acknowledgement Form to the patient.
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>provide each patient with appropriate instructions for taking LOTRONEX.
</li>
</ul>
<p style="border-left:1px solid;"><span class="XmChange"></span>Copies of the Patient Acknowledgement Form for LOTRONEX and additional copies of the Medication Guide are available by contacting Prometheus at 1-888-423-5227 or visiting www.lotronexppl.com.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline">Patients who are prescribed LOTRONEX should be instructed to:</span></p>
<ul class="Disc">
<li style="border-left:1px solid;">
<span class="XmChange"></span>read the Medication Guide before starting LOTRONEX and each time they refill their prescription.
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>not start taking LOTRONEX if they are constipated.
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>immediately discontinue LOTRONEX and contact their prescriber if they become constipated, or have symptoms of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> such as new or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, or blood in the stool. Contact their prescriber again if their <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> does not resolve after discontinuation of LOTRONEX. Resume LOTRONEX only if their <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> has resolved and after discussion with and the agreement of their treating prescriber.
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>stop taking LOTRONEX and contact their prescriber if LOTRONEX does not adequately control IBS symptoms after 4 weeks of taking 1 mg twice a day.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-16.2"></a><p></p>
<p class="First"><span class="Bold">Medication Guide</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="e61"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE<br>LOTRONEX (LOW-trah-nex) Tablets<br>(alosetron hydrochloride)</span></p>
<table width="100%">
<col align="left" width="100.000%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Before using LOTRONEX for the first time, you should:</span><br><ul class="Disc">
<li>Understand that LOTRONEX has serious risks for some people.
</li>
<li>Read and follow the directions in this Medication Guide.
</li>
<li>Sign a Patient Acknowledgement Form.<br>
</li>
</ul>
</td></tr></tbody>
</table>
<p>Read this Medication Guide carefully before you sign the Patient Acknowledgement Form . You must sign the Patient Acknowledgement Form  before you start LOTRONEX. Read the Medication Guide you get with each refill for LOTRONEX. There may be new information. This Medication Guide does not take the place of talking with your doctor.
</p>
<p><span class="Bold">1.
</span><span class="Bold Underline">What is the most important information I should know about LOTRONEX?</span></p>
<ol class="BigAlpha">
<li>
<span class="Bold">LOTRONEX is a medicine only for some women with severe chronic <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (IBS) whose:</span><ul class="Disc">
<li>main problem is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and
</li>
<li>IBS symptoms have not been helped enough by other treatments.
</li>
</ul>
</li>
<li>
<span class="Bold">Some patients have developed serious bowel side effects while taking LOTRONEX. Serious bowel (intestine) side effects can happen suddenly, including the following.</span><ol class="Arabic">
<li>
<span class="Bold">Serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>:</span> About 1 out of every 1,000 women who take LOTRONEX may get serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. These complications <span class="Bold">may lead to a hospital stay and, in rare cases, blood transfusions, surgery, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> People who are older, who are weak from illness, or who take other constipating medicines may be more likely to have serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> with LOTRONEX.<br><span class="Bold">To lower your chances of getting serious complications of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>,</span> do the following:<ul class="Disc">
<li>
<span class="Bold">If you are constipated</span>, do not start taking LOTRONEX.
</li>
<li>
<span class="Bold">If you get constipated while taking LOTRONEX</span>, stop taking it right away and call your doctor.
</li>
<li>
<span class="Bold">If your <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> does not get better after stopping LOTRONEX</span>, call your doctor again.
</li>
<li>
<span class="Bold">If you stopped taking LOTRONEX, do not start taking LOTRONEX again</span> unless your doctor tells you to do so.
</li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span>
</span><span class="Bold">(reduced blood flow to the bowel):</span> About 3 out of every 1,000 women who take LOTRONEX over a 6-month period may get a serious problem where blood flow to parts of the large bowel is reduced. This is called <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. The chance of getting <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span> when you take LOTRONEX for more than 6 months is not known. <span class="Bold"><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span> may lead to a hospital stay and, in rare cases, blood transfusions, surgery, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>.<br><span class="Bold">To lower your chances of getting serious complications of <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>, stop taking LOTRONEX and call your doctor right away if you get:</span><ul class="Disc">
<li>new or worse <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your stomach area (abdomen) or
</li>
<li>blood in your bowel movements.
</li>
</ul>
</li>
</ol>
</li>
<li>
<span class="Bold">Is LOTRONEX right for you?<br>LOTRONEX may be right for you if
</span><span class="Bold Underline">all
</span><span class="Bold">of these things are true about you:</span><ul class="Disc">
<li>Your doctor has told you that your symptoms are due to IBS.
</li>
<li>Your IBS bowel problem is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.
</li>
<li>Your IBS has lasted for 6 months or longer.
</li>
<li>You tried other IBS treatments and they did not give you the relief you need.
</li>
<li>Your IBS is severe. <br>You can tell if your IBS is severe if <span class="Bold Underline">at least 1</span> of the following is true for you:
</li>
<li>You have lots of painful <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> or <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>.
</li>
<li>You often cannot control the need to have a bowel movement, or you have “accidents? where your underwear gets dirty from <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or bowel movements.
</li>
<li>You cannot lead a normal home or work life because you need to be near a bathroom.<br>Enough testing has not been done to confirm if LOTRONEX works in men or children under age 18.
</li>
</ul>
</li>
<li><span class="Bold">There is a special prescribing program for LOTRONEX.</span></li>
</ol>
<p>Only doctors who have signed up with the company that makes LOTRONEX should write prescriptions for LOTRONEX. As part of signing up, these doctors have said that they understand about IBS and the possible side effects of LOTRONEX. They have agreed to use a special sticker on <span class="Bold Underline">written</span> prescriptions for LOTRONEX, so the pharmacist will know that the doctors have signed up with the company.  No telephone, facsimile, or computerized prescriptions are permitted with this program.  Refills may be written on prescriptions.
</p>
<p>You may be taught about LOTRONEX by your doctor or healthcare provider under a doctor's direction. Your doctor will ask you to sign a Patient Acknowledgement Form  after you read this Medication Guide for the first time. Signing the Patient Acknowledgement Form means that you understand the benefits and risks of LOTRONEX and that you have read and understand this Medication Guide.
</p>
<p><span class="Bold">2.
</span><span class="Bold Underline">What is LOTRONEX?</span></p>
<p>LOTRONEX is a medicine only for some women with severe chronic IBS whose:
</p>
<ul class="Disc">
<li>main problem is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and
</li>
<li>IBS symptoms have not been helped enough by other treatments.
</li>
</ul>
<p>LOTRONEX does not cure IBS, and it may not help every person who takes it. For those who are helped, LOTRONEX reduces lower stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, the sudden need to have a bowel movement (bowel urgency), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> from IBS. If you stop taking LOTRONEX, your IBS symptoms may return within 1 or 2 weeks to what they were before you started taking LOTRONEX.
</p>
<p>LOTRONEX is not recommended for children.
</p>
<p><span class="Bold">3.
</span><span class="Bold Underline">Who should not take LOTRONEX?</span></p>
<p>LOTRONEX is not right for everyone. <span class="Bold">Do not take LOTRONEX if
</span><span class="Bold Underline">any
</span><span class="Bold">of the following apply to you:</span></p>
<ul class="Disc">
<li>Your main IBS problem is <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or you are constipated most of the time.
</li>
<li>You have had a serious problem from <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.  <span class="Bold">If you are constipated now,
</span><span class="Bold Underline">do not start taking LOTRONEX</span>.
</li>
<li>You have had serious bowel blockages.
</li>
<li>You have had blood flow problems to your bowels, such as <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>.
</li>
<li>You have had blood clots.
</li>
<li>You have had Crohn's disease, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, or severe liver disease.
</li>
<li>You do not understand this Medication Guide or the Patient Acknowledgement Form, or you are not willing to follow them.
</li>
<li>You are taking fluvoxamine (LUVOX<span class="Sup">®</span>).
</li>
</ul>
<p><span class="Bold">4.
</span><span class="Bold Underline">What should I talk about with my doctor before taking LOTRONEX?</span></p>
<p>Talk with your doctor:
</p>
<ul class="Disc">
<li>about the possible benefits and risks of LOTRONEX.
</li>
<li>about how much of a problem IBS is in your life and what treatments you have tried.
</li>
<li>about any other illnesses you have and medicines you take or plan to take. These include prescription and non-prescription medicines, supplements, and herbal remedies. Certain illnesses and medicines can increase your chance of getting serious side effects while taking LOTRONEX. Other medicines may interact with how the body handles LOTRONEX.
</li>
<li>about any allergies that you have. See the end of the Medication Guide for a complete list of ingredients in LOTRONEX.
</li>
<li>if you are pregnant, planning to get pregnant, or breastfeeding.
</li>
</ul>
<p><span class="Bold">5.
</span><span class="Bold Underline">How should I take LOTRONEX</span><span class="Underline">?</span></p>
<ul class="Disc">
<li>Take LOTRONEX exactly as your doctor prescribes it. You can take LOTRONEX with or without food.
</li>
<li>Begin with 0.5 mg two times a day for 4 weeks to see how LOTRONEX affects you. You and your doctor may decide that you should keep taking this dose if you are doing well.
</li>
<li>Check with your doctor 4 weeks after starting LOTRONEX:<ul class="Disc">
<li>If you try 0.5 mg two times a day for 4 weeks, it may not control your symptoms. If you do not get <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or other side effects from LOTRONEX, your doctor may increase your dose up to 1 mg two times a day.
</li>
<li>If 1 mg two times a day does not work after 4 weeks, LOTRONEX is not likely to help you. You should stop taking it and call your doctor.
</li>
</ul>
</li>
<li>
<span class="Bold">If you miss a dose of LOTRONEX</span>, just skip that dose. Do <span class="Bold">not</span> take 2 doses the next time. Wait until the next time you are supposed to take it and then take your normal dose.
</li>
<li>
<span class="Bold">Follow the important instructions in the section “What is the most important information I should know about LOTRONEX??</span> about when you must stop taking the medicine and when you should call your doctor.
</li>
<li>
<span class="Bold">If you see other doctors</span> about your IBS or side effects from LOTRONEX, tell the doctor who prescribed LOTRONEX.
</li>
</ul>
<p><span class="Bold">6.
</span><span class="Bold Underline">What are the possible side effects of LOTRONEX?</span></p>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is the most common side effect among women with IBS who take LOTRONEX. <span class="Bold">Some patients have developed serious bowel side effects while taking LOTRONEX.</span> Read the section <span class="Bold">“What is the most important information I should know about LOTRONEX??</span> at the beginning of this Medication Guide for information about the serious side effects you may get with LOTRONEX.
</p>
<p>This Medication Guide does not tell you about all the possible side effects of LOTRONEX. Your doctor or pharmacist can give you a more complete list.
</p>
<p>Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold Underline">7. How should I store LOTRONEX?</span></p>
<ul class="Disc">
<li>Store LOTRONEX between 59ºF to 86ºF (15ºC to 30ºC).
</li>
<li>Protect LOTRONEX from light and getting wet (moisture).
</li>
</ul>
<p><span class="Bold">Keep LOTRONEX and all medicines out of the reach of children.</span></p>
<p><span class="Bold">8.
</span><span class="Bold Underline">General information about the safe and effective use of LOTRONEX</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you have any questions or concerns about LOTRONEX, ask your doctor. Do not use LOTRONEX for a condition for which it was not prescribed. Do not share your medicine with other people. It may harm them.<br>Your doctor or pharmacist can give you more information about LOTRONEX that was written for healthcare professionals. You can also contact the company that makes LOTRONEX (toll free) at 1-888-423-5227 or at www.lotronexppl.com.
</p>
<p><span class="Bold">9.
</span><span class="Bold Underline">What are the ingredients of LOTRONEX?</span></p>
<p><span class="Bold">Active Ingredient:</span> alosetron hydrochloride.
</p>
<p><span class="Bold">Inactive Ingredients:</span> lactose (anhydrous), magnesium stearate, microcrystalline cellulose, and pregelatinized starch. The white film-coat for the 0.5 mg tablet contains hypromellose, titanium dioxide, and triacetin. The blue film-coat for the 1 mg tablet contains hypromellose, titanium dioxide, triacetin, and indigo carmine.
</p>
<p>Manufactured for:<br>Prometheus Laboratories Inc.<br>9410 Carroll Park Drive<br>San Diego, CA 92121
</p>
<p><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Revised September 2010<br>LX002D
</p>
<p>Prometheus Laboratories Inc.<br>San Diego, CA 92121
</p>
<p>Made in CANADA
</p>
<p>©2008-2014, Prometheus Laboratories Inc. All rights reserved.
</p>
<p>This product may be covered by one or more US pending or issued patents.<br>For details, contact www.prometheuslabs.com
</p>
<p>Prometheus and LOTRONEX are registered trademarks of Prometheus Laboratories Inc.
</p>
<p>LUVOX is a registered trademark of Abbott Products, Inc.</p>
<p>March 2014<br>LX001E
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s64"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Lotronex 0.5 mg Bottle Label</span></p>
<p>NDC 65483-894-03<br>30 Tablets<br>LOTRONEX<br>(alosetron hydrochloride) Tablets 0.5mg<br>Each film-coated tablet contains alosetron<br>hydrochloride equivalent to 0.5 mg alosetron.<br>Rx only<br>See prescribing information<br>For Dosage and Administration
</p>
<p>Store at 20-25˚C (68-77˚F) (USP Controlled Room Temperature)
</p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel - Lotronex 0.5 mg Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526ba44c-a476-4675-a63c-4d0a72b723f5&amp;name=lot00-0007-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s65"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Lotronex 0.5 mg Carton</span></p>
<p>NDC 65483-894-03<br>30 Tablets<br>LOTRONEX<br>(alosetron hydrochloride)<br>Tablets<br>Rx Only 0.5 mg<br>Each film-coated tablet contains alosetron<br>hydrochloride equivalent to 0.5 mg alosetron.
</p>
<p>Pharmacist Affix Label Here:
</p>
<p>Federal Law requires the dispensing<br>of LOTRONEX ® with the Medication<br>Guide included in this box.
</p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel - Lotronex 0.5 mg Carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526ba44c-a476-4675-a63c-4d0a72b723f5&amp;name=lot00-0007-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s66"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Lotronex 1 mg Bottle Label</span></p>
<p>NDC 65483-895-03<br>30 Tablets<br>LOTRONEX<br>(alosetron hydrochloride) Tablets 1 mg<br>Each film-coated tablet contains alosetron hydrochloride<br>equivalent to 1 mg alosetron.<br>Rx only<br>See prescribing information<br>For Dosage and Administration.
</p>
<p>Store at 20-25˚C (68-77˚F) (USP Controlled Room Temperature)
</p>
<div class="Figure">
<a name="f05"></a><img alt="Principal Display Panel - Lotronex 1 mg Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526ba44c-a476-4675-a63c-4d0a72b723f5&amp;name=lot00-0007-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s67"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Lotronex 1 mg Carton</span></p>
<p>NDC 65483-895-03<br>30 Tablets<br>LOTRONEX<br>(alosetron hydrochloride)<br>Tablets<br>Rx Only 1 mg<br>Each film-coated tablet contains alosetron<br>hydrochloride equivalent to 1 mg alosetron.
</p>
<p>Pharmacist Affix Label Here:
</p>
<p>Federal Law requires the dispensing<br>of LOTRONEX ® with the Medication<br>Guide included in this box.
</p>
<div class="Figure">
<a name="f06"></a><img alt="Principal Display Panel - Lotronex 1 mg Carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526ba44c-a476-4675-a63c-4d0a72b723f5&amp;name=lot00-0007-06.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOTRONEX 		
					</strong><br><span class="contentTableReg">alosetron hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65483-894</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>alosetron hydrochloride</strong> (alosetron) </td>
<td class="formItem">alosetron</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>triacetin</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GX;EX1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65483-894-03</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021107</td>
<td class="formItem">02/09/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOTRONEX 		
					</strong><br><span class="contentTableReg">alosetron hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65483-895</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>alosetron hydrochloride</strong> (alosetron) </td>
<td class="formItem">alosetron</td>
<td class="formItem">1.0 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>triacetin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>indigotindisulfonate sodium</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GX;CT1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65483-895-03</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021107</td>
<td class="formItem">02/09/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Prometheus Laboratories Inc.
							(967000860)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Inc.</td>
<td class="formItem"></td>
<td class="formItem">240769596</td>
<td class="formItem">MANUFACTURE(65483-894, 65483-895)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>66cf41ae-b5a3-49ad-8134-de50360b1040</div>
<div>Set id: 526ba44c-a476-4675-a63c-4d0a72b723f5</div>
<div>Version: 9</div>
<div>Effective Time: 20140331</div>
</div>
</div> <div class="DistributorName">Prometheus Laboratories Inc.</div></p>
</body></html>
